PRIMARY SCLEROSING CHOLANGITIS MARKET ANALYSIS

Primary sclerosing cholangitis Market, By Drug Class (Ursodeoxycholic acid (UDCA), Corticosteroids, Azathioprine, Mercaptopurine, Budesonide, Obeticholic acid, Monoclonal antibody, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In March 2024, LISCure Biosciences, a clinical-stage pharmaceutical company, had received Fast Track designation from the FDA for LB-P8, its investigational drug aimed at treating primary sclerosing cholangitis (PSC). PSC is a rare and chronic liver disease with limited treatment options, making this designation significant for advancing potential therapies in this area.
In June 20224, PSC Partners and PSC Partners Canada have announced the enrollment of the first patient in the WIND-PSC study, aimed at addressing primary sclerosing cholangitis (PSC), a rare and serious chronic liver disease. With no approved therapies available, the study aims to generate crucial data to aid in the development of new treatments, thereby improving outcomes for patients facing significant health challenges.
In November 2023, Chemomab Therapeutics Ltd., a biotech company, announced that its drug CM-101 has received Fast Track designation from the USFDA for treating primary sclerosing cholangitis (PSC) in adult patients.